Becton, Dickinson and Company (BDX) AI Stock Analysis

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It serves healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the public. The BD Medical segment provides peripheral intravenous catheters, vascular access devices, medication delivery systems, automated dispensing equipment, and diabetes care products. The BD Life Sciences segment offers specimen collection products, automated blood culturing, molecular testing, diagnostic assays, cell sorters, and reagents. The BD Interventional segment delivers devices for hernia and soft tissue repair, as well as surgical infection prevention.

Between FY2020 and FY2025, BDX grew revenue at a 5-year CAGR of 6.3%, reaching $21.84B in FY2025 with an 8.2% annual increase. Gross margin was 45.4% in FY2025, slightly higher than 45.2% in FY2024 and 42.2% in FY2023. Operating margin was 11.8% in FY2025, while net income totaled $1.68B and diluted EPS reached $14.42. For the trailing twelve months, revenue was $22.48B with a profit margin of 4.2% and EPS of $4.30. In the latest quarter ended June 30, 2026, revenue increased 5.4% year-over-year, while quarterly earnings fell 31.4%.

As of June 30, 2026, BDX held $709.0M in cash and short-term investments compared to $16.81B in total debt, leaving net debt at $16.10B. Shareholders' equity was $24.42B, resulting in a debt-to-equity ratio of 0.69, while the current ratio stood at 0.87. In FY2025, operating cash flow reached $3.43B and free cash flow was $2.67B. Capital expenditures were $760.0M, share buybacks totaled $1.00B, and dividends paid were $1.20B. Over the last five years, the company reduced its share count by 4.0%.

At a share price of $191.75, BDX has a market capitalization of $52.23B and an enterprise value of $65.82B. The stock trades at a trailing P/E of 44.6x, above the median of its S&P 500 Healthcare peers at 27.2x. Its forward P/E of 13.7x and EV/EBITDA of 13.4x sit below the peer medians of 16.6x and 15.7x, respectively. The price-to-sales ratio is 2.3x versus the peer median of 3.4x. Over the past year, BDX gained 34.9%, outperforming the S&P 500 SPY return of 16.8%, though its 5-year return of 13.4% lagged the benchmark return of 83.0%.

BDX pays an annualized forward dividend of $4.20 per share, representing a 2.19% dividend yield and a payout ratio of 30.6%. The company has paid consecutive dividends for 44 years. Over the last five years, its dividend grew at an annualized rate of 6.0%. The last ex-dividend date was September 9, 2026.

Wall Street analysts covering BDX include 6 Strong Buys, 1 Buy, 7 Holds, and 1 Sell. The mean price target of $194.08 implies 1.2% upside from the last close of $191.75. For the current fiscal year ending September 30, 2026, analysts estimate EPS of $12.63, a decline of 12.3%, on revenue of $19.28B. For the next fiscal year, 15 analysts project EPS to grow 5.3% to $13.30 and revenue to grow 2.4% to $19.74B. BDX has beaten EPS estimates in each of the last 4 quarters, and the next earnings date is November 5, 2026.

This page is an AI-written research summary of Becton, Dickinson and Company (BDX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: BDX income statement, BDX balance sheet, BDX key metrics, BDX analyst forecast, BDX chart. See the BDX stock overview for the latest quote and news.